Navigation Links
ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011
Date:5/9/2011

SHANGHAI, May 9, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the first quarter 2011 ended March 31, 2011 on May 19, 2011. Management will host a conference call to discuss the results at 8:00am New York Time on May 19, 2011 (8:00pm Beijing time on May 19, 2011).

Conference Call Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, and Mr. William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:- U.S. Toll Free Number:  

1.888.396.2369- International dial-in number:1.617.847.8710- China Toll Free Number:

10 800 152 1490 (North)10 800 852 1490 (South)- Hong Kong Toll Free Number:

800 96 3844Passcode:

SHPA live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from May 19, 2011 to May 26, 2011. The dial-in details for the replay are as follows: - U.S. Toll Free Number:

1-888-286-8010- International dial-in number:1-617-801-6888Passcode:

64510327About ShangPharma Corp.ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, contact:ShangPharma CorporationLan Xie, VP of Finance and OperationsE-mail: IR@shangpharma.comChristensenIn New YorkKimberly Minarovich,Phone: +1 917-533-3268E-mail: kminarovich@christensenir.comIn Hong KongTip FlemingPhone: +852-9212-0684Email: tfleming@ChristensenIR.com  
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
2. ShangPharma to Present at the Citibank Global Health Care Conference from March 1 - 3, 2011
3. ShangPharma Announces Fourth Quarter and Fiscal Year 2010 Results
4. ShangPharma Corporation Files 2010 Annual Report on Form 20-F
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. CEL-SCI Corporation Releases Letter to Shareholders
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... , ... April 21, 2017 , ... An April 10 ... a pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental ... sharp stone may have been used to remove decayed dental matter, and that teeth ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... ... 21, 2017 , ... Dudnyk has announced the launch of its new brand ... full potential of specialty and orphan brands can only be achieved when the needs ... Unifying Effect is at the heart of a true partnership between our agency and ...
(Date:4/21/2017)... ... , ... The Hong Kong Polytechnic University (PolyU) launched today the University Research ... in Hong Kong to support teaching, learning and research. It is also the largest ... in Hong Kong. , With an area of 620 square metres and more ...
Breaking Medicine News(10 mins):